BioSpace News Archive

Guardant Health announces reimbursement approval of Guardant360 ® CDx liquid biopsy test in Japan.

ReWalk Robotics Ltd. announced that it will host a conference call and webcast on Tuesday, July 11, 2023 to discuss the recent proposal from the Centers for Medicare & Medicaid Services (“CMS”) to include personal exoskeletons in the Medicare benefit category for braces as part of the Calendar Year 2024 Home Health Prospective Payment System Proposed Rule, CMS-1780-P (“Proposed Rule”), released on June 30, 2023.

Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) is pleased to announce that it has been granted final approval for its double blind, placebo controlled Phase II Clinical Trial for the treatment of Autism Spectrum Disorder (ASD) from the Israel Ministry of Health.

The Preeclampsia Foundation is seeking Letters of Intent for the Peter Joseph Pappas Research Grants funding program, designed to accelerate preeclampsia research.

Genprex, Inc. today announced that the China National Intellectual Property Administration has granted Genprex China Patent No: 201780076886.X.

Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the appointment of Dr. Fred Grossman to its senior management team as President and Chief Medical Officer.

Xenetic Biosciences, Inc. today announced that Jeffrey Eisenberg, Chief Executive Officer and Curtis A. Lockshin, PhD, Chief Scientific Officer of Xenetic Biosciences will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 10:00 AM ET.

Salvia BioElectronics, a pioneering company focused on neuromodulation for severe migraine, announced the successful first implantation of their paper-thin neuromodulation solution.

The Kleine-Levin Syndrome Foundation today announced updated diagnostic criteria for Kleine-Levin Syndrome (KLS) published in the International Classification of Sleep Disorders Third Edition.

H.C. Wainwright & Co, reiterated its buy rating on Agile Therapeutics, Inc. (NASDAQ:AGRX) this month, setting a price target of $12 per share.